Enliven Therapeutics (ELVN) Change in Acquisitions & Divestments (2020 - 2026)

Enliven Therapeutics (ELVN) has 7 years of Change in Acquisitions & Divestments data on file, last reported at $108.4 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 78.6% year-over-year to $108.4 million; the trailing twelve-month figure through Mar 2026 stood at $320.6 million (down 4.49% YoY), and the FY2025 full-year result was $272.9 million, down 13.07% from the prior year.
• Change in Acquisitions & Divestments improved to $108.4 million in Q1 2026, from $87.7 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $117.2 million in Q4 2024 to a low of -$12.0 million in Q3 2022.
• A 5-year average of $58.2 million and a median of $64.2 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• Across the five-year window, Change in Acquisitions & Divestments slumped 189.2% in 2022 and soared 434.64% in 2023, its largest moves.
• Tracing ELVN's Change in Acquisitions & Divestments over 5 years: stood at -$12.0 million in 2022, then soared by 769.29% to $80.0 million in 2023, then surged by 46.55% to $117.2 million in 2024, then retreated by 25.21% to $87.7 million in 2025, then advanced by 23.58% to $108.4 million in 2026.
• Business Quant data shows ELVN's Change in Acquisitions & Divestments at $108.4 million in Q1 2026, $87.7 million in Q4 2025, and $67.8 million in Q3 2025.